Beat it early: Putative renoprotective haemodynamic effects of oral hypoglycaemic agents

Nephrology Dialysis Transplantation

Volumn 31, Issue 7, 2016, Pages 1036-1043

  Gnudi, Luigi ^a   Karalliedde, Janaka ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetic kidney disease; DPP 4 inhibitor; GLP 1 receptor agonists; Renoprotection; SGLT 2 inhibitor

Indexed keywords

DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LINAGLIPTIN; ORAL ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT;

ALBUMINURIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE HOMEOSTASIS; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84983803045     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv093     Document Type: Article

References (66)

1. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787-835, ix
2. IDF Diabetes Atlas 6E. International Diabetes Foundation. 2013
3. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-412
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986
5. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and in patients with type 2 diabetes. N Engl J Med 2003;348:383-393
6. Bianchi C, Del PS. Metabolic memory and individual treatment aims in type 2 diabetes-outcome-lessons learned from large clinical trials. Rev Diabet Stud 2011;8:432-440
7. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
8. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
9. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
10. UKPDS. UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 1990;13:1-11
11. The Hypertension in Diabetes study group. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993;11:309-317
12. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010;27:136-142
13. Meyer C, Dostou JM, Welle SL et al. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab 2002;282:E419-E427
14. DeFronzo RA, Davidson JA, Del PS. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14
15. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43
16. Meyer C, Woerle HJ, Dostou JM et al. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab 2004;287:E1049-E1056
17. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971;28:101-109
18. Rahmoune H, Thompson PW, Ward JM et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-3434
19. Bautista R, Manning R, Martinez F et al. Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension. Am J Physiol Renal Physiol 2004;286:F127-F133
20. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 1984;27:351-357
21. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305
22. Collins AJ, Foley RN, Chavers B et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 2012;59:A7, e1-A7, 420
23. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232
24. Middleton RJ, Foley RN, Hegarty J et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant 2006;21:88-92
25. Bailey RA, Wang Y, Zhu V et al. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes 2014;7:415
26. Foley RN, Murray AM, Li S et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-495
27. Ruggenenti P, Porrini E, Motterlini N et al. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol 2012;23:1717-1724
28. Wang SL, Head J, Stevens L et al. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organization multinational study of vascular disease in diabetes. Diabetes Care 1996;19:305-312
29. Gnudi L. Cellular and molecular mechanisms of diabetic glomerulopathy. Nephrol Dial Transplant 2012;27:2642-2649
30. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013;93:137-188
31. De CS, Menzaghi C, Prudente S et al. Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence. Nephrol Dial Transplant 2013;28:29-36
32. Okada R, Yasuda Y, Tsushita K et al. Glomerular hyperfiltration in prediabetes and prehypertension. Nephrol Dial Transplant 2012;27:1821-1825
33. Palatini P. Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 2012;27:1708-1714
34. Jerums G, Premaratne E, Panagiotopoulos S et al. The clinical significance of hyperfiltration in diabetes. Diabetologia 2010;53:2093-2104
35. Ruggenenti P, Porrini EL, Gaspari F et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012;35:2061-2068
36. Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation 2014;129:542-544
37. Gnudi L, Thomas SM, Viberti G. Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. JAmSoc Nephrol 2007;18:2226-2232
38. Panchapakesan U, Pegg K, Gross S et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS One 2013;8:e54442
39. Molitch ME, DeFronzo RA, Franz MJ et al. Nephropathy in diabetes. Diabetes Care 2004;27(Suppl 1):S79-S83
40. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in peoplewith diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259
41. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
42. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878
43. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
44. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006;17:S90-S97
45. DeFronzo RA, Hompesch M, Kasichayanula S et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 2013;36:3169-3176
46. Sha S, Devineni D, Ghosh A et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 2011;13:669-672
47. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010;95:34-42
48. Thomson SC, Rieg T, Miracle C et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012;302:R75-R83
49. Vallon V, Rose M, Gerasimova M et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013;304:F156-F167
50. Vallon V, Gerasimova M, Rose MA et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014;306:F194-F204
51. Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-597
52. Burrell LM, Johnston CI, Tikellis C et al. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004;15:166-169
53. Kojima N, Williams JM, Takahashi T et al. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 2013;345:464-472
54. Groop PH, Cooper ME, Perkovic V et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013;36:3460-3468
55. Kanasaki K, Shi S, Kanasaki M et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 2014;63:2120-2131
56. Kodera R, Shikata K, Kataoka HU et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965-978
57. Chaudhuri A, Ghanim H, Vora M et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 2012;97:198-207
58. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009;94:3171-3182
59. Polidori D, Sha S, Mudaliar S et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebocontrolled study. Diabetes Care 2013;36:2154-2161
60. Kim M, Platt MJ, Shibasaki T et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013;19:567-575
61. Wang B, Zhong J, Lin H et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013;15:737-749
62. Ban K, Hui S, Drucker DJ et al. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 2009;3:245-259
63. Gallwitz B. Preclinical and clinical data on extraglycemic effects of GLP-1 receptor agonists. Rev Diabet Stud 2009;6:247-259
64. Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord 2014;15:197-207
65. Skov J, Dejgaard A, Frokiaer J et al. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 2013;98:E664-E671
66. Lovshin JA, Barnie A, DeAlmeida A et al. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic Peptide in hypertensive subjects with type 2 diabetes. Diabetes Care 2015;38:132-139